XML 15 R4.htm IDEA: XBRL DOCUMENT v3.3.1.900
Condensed Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2015
Dec. 31, 2014
Income Statement [Abstract]        
Molecular diagnostic testing $ 182.6 $ 179.2 $ 354.5 $ 343.6
Pharmaceutical and clinical services 10.7 5.2 22.3 9.6
Total revenue 193.3 184.4 376.8 353.2
Costs and expenses:        
Cost of molecular diagnostic testing 34.1 35.1 65.0 67.8
Cost of pharmaceutical and clinical services 6.5 2.8 12.1 4.9
Research and development expense 16.7 17.5 33.9 40.1
Selling, general, and administrative expense 90.8 92.7 177.3 178.1
Total costs and expenses 148.1 148.1 288.3 290.9
Operating income 45.2 36.3 88.5 62.3
Other income (expense):        
Interest income 0.1 0.1 0.2 0.1
Other (0.3) 1.5 (0.1) 1.4
Total other income (expense): (0.2) 1.6 0.1 1.5
Income before income tax 45.0 37.9 88.6 63.8
Income tax provision 14.7 13.9 31.6 23.8
Net income $ 30.3 $ 24.0 $ 57.0 $ 40.0
Earnings per share:        
Basic $ 0.43 $ 0.33 $ 0.82 $ 0.55
Diluted $ 0.41 $ 0.32 $ 0.78 $ 0.53
Weighted average shares outstanding:        
Basic 70.5 72.5 69.6 72.6
Diluted 73.8 75.4 73.1 75.8